Disproportionality in reporting herpes zoster infection was higher for patients receiving fingolimod compared with those receiving other disease-modifying treatments ( empirical Bayes geometric mean , 2.57 [ 90 % CI , 2.26-2 .91 ] ) ; the proportion of serious herpes zoster infections was not higher than the proportion for other treatments ( empirical Bayes geometric mean , 1.88 [ 90 % CI , 0.87-3 .70 ] ) .